secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2022-11-18T23:59:59+00:00
Accession:  0001104659-22-120391
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance signs $500M at-the-market equity offering with Jefferies, replacing prior facility
--------------------------------------------------------------------------------

- New Open Market Sale Agreement with Jefferies allows sale of up to $500M in common stock at the market.
- Prior ATM agreement dated February 8, 2021 was terminated concurrent with the new agreement.
- Jefferies will receive up to 3.0% commission on gross proceeds from any shares sold.
- Sales are discretionary; the company is not obligated to sell any shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465922120391/0001104659-22-120391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465922120391/tm2230330d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-120391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer